BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα pathway cancers. The company specializes in precision oncology by creating innovative approaches to address historically difficult-to-drug targets, including direct KRAS inhibitors that bind to both active and inactive protein states, PI3Kα:RAS interaction breakers designed to block specific signaling cascades while minimizing metabolic side effects, and pan-KRAS inhibitors targeting multiple KRAS mutations. BridgeBio Oncology Therapeutics currently has multiple programs in clinical development, including candidates for non-small cell lung cancer, colorectal cancer, and breast cancer. Originally established as a subsidiary of BridgeBio Pharma in 2016, the company became a standalone public entity in 2025 through a business combination. Based in South San Francisco, BridgeBio Oncology Therapeutics applies advanced understanding of RAS signaling biology to rational drug design, aiming to deliver well-tolerated medicines with greater efficacy and safety for patients with cancers driven by the two most prevalent oncogenes in human tumors.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Eli M. Wallace Ph.D.

Employees

106

Headquarters

South San Francisco, CA, United States

Website

bbotx.com